跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Bravifo - Philippines FDA Drug Approval Details
Approvals
/
Philippines FDA
/
Bravifo
Approved
STANDARD
Bravifo
MSN Laboratories Private Limited (Formulations Division)
🇵🇭 Food and Drug Administration - Philippines
Approval Date
Jul 14, 2025
Approval ID
0da09ede1fa67666
Company
MSN Laboratories Private Limited (Formulations Division)
Type
Standard
Approval Details
Approval Id
0da09ede1fa67666
Drug Approval Philippines Name
Bravifo
Product Name
Bravifo
Registration Number
DR-XY47844
Brand Name
Bravifo
Generic Name
Paclitaxel
Dosage Form
Solution for Infusion
Dosage Strength
6 mg / mL (30 mg / 5 mL)
Manufacturer
MSN Laboratories Private Limited (Formulations Division)
Importer
Mega Lifesciences Limited, Inc.
Distributor
Metro Drug, Inc.
Issuance Date
29 March 2022
Expiry Date
29 March 2027
Pharmacologic Category
Antineoplastic Agent (Taxane)
Classification
Prescription Drug (RX)
Active Ingredients
Approved
Quick Info
Agency
Philippines FDA
Country
🇵🇭
Approval Date
Jul 14, 2025
Approval ID
0da09ede1fa67666
Type
Standard
Back to Philippines FDA Approvals